Immunitybio (IBRX) Stocktwits Mentions Statistics 2024

52 10.3%

1W 26.8% 1M 42.2% 3M 23.5%

Est. daily mentions on Stocktwits.

Similar companies

Company		Stocktwits Mentions
	Amgen AMGN	17 88.9%
	Gilead Sciences GILD	8 33.3%
	Catalyst Pharmaceuticals CPRX	2 0%
	Inovio Pharmaceuticals INO	22 24.1%
	Anavex Life Sciences AVXL	91 75%

Month over Month

Est. daily mentions on Stocktwits.

Oct 2024	79	41%
Sep 2024	56	19.2%
Aug 2024	69	18.4%
Jul 2024	59	12.7%
Jun 2024	52

How often is Immunitybio mentioned on StockTwits?

Immunitybio was mentioned an estimated 52 times in discussions on StockTwits yesterday.

Analyzing Stocktwits Mentions, how is Immunitybio performing compared to its industry peers?

Immunitybio underperforms its industry peers when it comes to Stocktwits Mentions, ranking in the 11th percentile.

What does a high frequency of StockTwits mentions indicate for Immunitybio's market sentiment?

A high frequency of mentions on StockTwits for Immunitybio could indicate strong market interest or sentiment towards the company. It often reflects the trading community's engagement with Immunitybio's stock, potentially signaling bullish or bearish trends based on the context of the discussions.

How often does AltIndex update information on Immunitybio's mentions on StockTwits?

AltIndex updates the data on Immunitybio's mentions on StockTwits daily. This frequent update schedule ensures that investors have access to the most current insights into market sentiment and discussion dynamics related to Immunitybio's on the platform.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.